J&J applies for vaccine trials in children aged 12-17 in India
NEW DELHI: American pharma giant Johnson & Johnson (J&J) has sought approval from India’s drugs regulator to conduct clinical trials of its Covid-19 vaccine for children in the 12-17 age group in the country.
J&J submitted an application to the Central Drugs Standard Control Organisation (CDSCO) on Tuesday, August 17, to conduct the trials of its single-dose coronavirus vaccine, the company said on Friday.
“Johnson & Johnson is committed to facilitating global equitable access to its Covid-19 vaccine and recognises the unmet needs of children,” said J&J India spokesperson in a statement.
“To ultimately achieve herd immunity, it is imperative that Covid-19 vaccine clinical trials continue to move forward in this population...” it said.
On August 7, the Drugs Controller General of India granted J&J’s Covid vaccine emergency use authorisation for adults.
It is the fifth vaccine and the second foreign-made after Moderna to receive emergency use authorisation.
There are currently two vaccine candidates that have been tested among children in India: Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCov-D.
NEW DELHI : American pharma giant Johnson & Johnson (J&J) has sought approval from India’s drugs regulator to conduct clinical trials of its Covid-19 vaccine for the people in the 12-17 age group in the country.
The company submitted an application to the Central Drugs Standard Control Organisation (CDSCO) on Tuesday, August 17, to conduct the trials of J&J’s single-dose Covid-19 vaccine.
J&J has confirmed the development. “Johnson & Johnson is committed to facilitating global equitable access to its Covid-19 vaccine and recognises the unmet needs of children. On 17 August 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson Covid-19 vaccine in India in adolescents aged 12-17 years,” said J&J India spokesperson in a statement.
“To ultimately achieve herd immunity, it is imperative that Covid-19 vaccine clinical trials continue to move forward in this population, and we remain deeply committed to the critical work needed to make our Covid-19 vaccine equitably accessible for all age groups.”
On August 7, the Drugs Controller General of India granted J&J’s Covid vaccine emergency use authorisation for adults. It is the fifth vaccine and the second foreign-made after Moderna’s to receive such authorisation.
If permitted, J&J’s would be the third Covid-19 vaccine to be tested for use in children in India. There are two vaccine candidates that have been tested among children in India: Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCov-D. The Covaxin trial includes 525 volunteers while ZyCov-D’s trials – as part of phase II/III clinical studies – include 1,000 volunteers in 12-18 age group. There are 145.4 million people in India between the ages of 12 and 18 (excluding 18).
J&J entered a partnership with India’s Hyderabad-based Biological E earlier this year to conduct a clinical trial and produce its Covid-19 vaccine in India.